Methylation of the CD44 metastasis suppressor gene in human prostate cancer

Wei Lou, Diane Krill, Rajiv Dhir, Michael J. Becich, Jin Tang Dong, Henry F. Frierson, William B. Isaacs, John T. Isaacs, Allen C Gao

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Previous studies demonstrated that CD44 is a metastasis suppressor gene for prostate cancer and that the expression of CD44 both at mRNA and protein levels is down-regulated during prostate cancer progression, with down- regulation being correlated with higher tumor grade, aneuploidy, and distant metastasis. In this study, we evaluated DNA hypermethylation as a potential mechanism accompanying this decreased CD44 expression in human prostate cancer. Nucleotide sequence analysis revealed a CpG island in the CD44 transcriptional regulatory region. We found that cytosine methylation of CD44 promoter occurs in CD44-negative prostate cancer cell line (i.e., LNCaP) but not in prostate cancer cell lines (i.e., TSU, PC3, and DU145) expressing this gene. In addition, we examined methylation status of CD44 in 84 matched normal and cancer prostate specimens. Hypermethylation of the 5' CpG island of CD44 gene was observed in 31 of 40 primary prostate cancer specimens, 3 of 4 distant organ site metastases obtained at autopsy from men died of prostate cancer, and 4 of the 40 matched normal tissues. These results demonstrated that methylation of the 5' CpG island of CD44 gene is closely associated with transcriptional inactivation, resulting in a decreased expression of CD44 in human prostate cancer.

Original languageEnglish (US)
Pages (from-to)2329-2331
Number of pages3
JournalCancer Research
Volume59
Issue number10
StatePublished - May 15 1999
Externally publishedYes

Fingerprint

Tumor Suppressor Genes
Methylation
Prostatic Neoplasms
CpG Islands
Neoplasm Metastasis
Genes
Cell Line
Nucleic Acid Regulatory Sequences
Cytosine
Aneuploidy
Sequence Analysis
Autopsy
Down-Regulation
Messenger RNA
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lou, W., Krill, D., Dhir, R., Becich, M. J., Dong, J. T., Frierson, H. F., ... Gao, A. C. (1999). Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Research, 59(10), 2329-2331.

Methylation of the CD44 metastasis suppressor gene in human prostate cancer. / Lou, Wei; Krill, Diane; Dhir, Rajiv; Becich, Michael J.; Dong, Jin Tang; Frierson, Henry F.; Isaacs, William B.; Isaacs, John T.; Gao, Allen C.

In: Cancer Research, Vol. 59, No. 10, 15.05.1999, p. 2329-2331.

Research output: Contribution to journalArticle

Lou, W, Krill, D, Dhir, R, Becich, MJ, Dong, JT, Frierson, HF, Isaacs, WB, Isaacs, JT & Gao, AC 1999, 'Methylation of the CD44 metastasis suppressor gene in human prostate cancer', Cancer Research, vol. 59, no. 10, pp. 2329-2331.
Lou W, Krill D, Dhir R, Becich MJ, Dong JT, Frierson HF et al. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Research. 1999 May 15;59(10):2329-2331.
Lou, Wei ; Krill, Diane ; Dhir, Rajiv ; Becich, Michael J. ; Dong, Jin Tang ; Frierson, Henry F. ; Isaacs, William B. ; Isaacs, John T. ; Gao, Allen C. / Methylation of the CD44 metastasis suppressor gene in human prostate cancer. In: Cancer Research. 1999 ; Vol. 59, No. 10. pp. 2329-2331.
@article{1642762fcb41474f9ff38cd01914176f,
title = "Methylation of the CD44 metastasis suppressor gene in human prostate cancer",
abstract = "Previous studies demonstrated that CD44 is a metastasis suppressor gene for prostate cancer and that the expression of CD44 both at mRNA and protein levels is down-regulated during prostate cancer progression, with down- regulation being correlated with higher tumor grade, aneuploidy, and distant metastasis. In this study, we evaluated DNA hypermethylation as a potential mechanism accompanying this decreased CD44 expression in human prostate cancer. Nucleotide sequence analysis revealed a CpG island in the CD44 transcriptional regulatory region. We found that cytosine methylation of CD44 promoter occurs in CD44-negative prostate cancer cell line (i.e., LNCaP) but not in prostate cancer cell lines (i.e., TSU, PC3, and DU145) expressing this gene. In addition, we examined methylation status of CD44 in 84 matched normal and cancer prostate specimens. Hypermethylation of the 5' CpG island of CD44 gene was observed in 31 of 40 primary prostate cancer specimens, 3 of 4 distant organ site metastases obtained at autopsy from men died of prostate cancer, and 4 of the 40 matched normal tissues. These results demonstrated that methylation of the 5' CpG island of CD44 gene is closely associated with transcriptional inactivation, resulting in a decreased expression of CD44 in human prostate cancer.",
author = "Wei Lou and Diane Krill and Rajiv Dhir and Becich, {Michael J.} and Dong, {Jin Tang} and Frierson, {Henry F.} and Isaacs, {William B.} and Isaacs, {John T.} and Gao, {Allen C}",
year = "1999",
month = "5",
day = "15",
language = "English (US)",
volume = "59",
pages = "2329--2331",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Methylation of the CD44 metastasis suppressor gene in human prostate cancer

AU - Lou, Wei

AU - Krill, Diane

AU - Dhir, Rajiv

AU - Becich, Michael J.

AU - Dong, Jin Tang

AU - Frierson, Henry F.

AU - Isaacs, William B.

AU - Isaacs, John T.

AU - Gao, Allen C

PY - 1999/5/15

Y1 - 1999/5/15

N2 - Previous studies demonstrated that CD44 is a metastasis suppressor gene for prostate cancer and that the expression of CD44 both at mRNA and protein levels is down-regulated during prostate cancer progression, with down- regulation being correlated with higher tumor grade, aneuploidy, and distant metastasis. In this study, we evaluated DNA hypermethylation as a potential mechanism accompanying this decreased CD44 expression in human prostate cancer. Nucleotide sequence analysis revealed a CpG island in the CD44 transcriptional regulatory region. We found that cytosine methylation of CD44 promoter occurs in CD44-negative prostate cancer cell line (i.e., LNCaP) but not in prostate cancer cell lines (i.e., TSU, PC3, and DU145) expressing this gene. In addition, we examined methylation status of CD44 in 84 matched normal and cancer prostate specimens. Hypermethylation of the 5' CpG island of CD44 gene was observed in 31 of 40 primary prostate cancer specimens, 3 of 4 distant organ site metastases obtained at autopsy from men died of prostate cancer, and 4 of the 40 matched normal tissues. These results demonstrated that methylation of the 5' CpG island of CD44 gene is closely associated with transcriptional inactivation, resulting in a decreased expression of CD44 in human prostate cancer.

AB - Previous studies demonstrated that CD44 is a metastasis suppressor gene for prostate cancer and that the expression of CD44 both at mRNA and protein levels is down-regulated during prostate cancer progression, with down- regulation being correlated with higher tumor grade, aneuploidy, and distant metastasis. In this study, we evaluated DNA hypermethylation as a potential mechanism accompanying this decreased CD44 expression in human prostate cancer. Nucleotide sequence analysis revealed a CpG island in the CD44 transcriptional regulatory region. We found that cytosine methylation of CD44 promoter occurs in CD44-negative prostate cancer cell line (i.e., LNCaP) but not in prostate cancer cell lines (i.e., TSU, PC3, and DU145) expressing this gene. In addition, we examined methylation status of CD44 in 84 matched normal and cancer prostate specimens. Hypermethylation of the 5' CpG island of CD44 gene was observed in 31 of 40 primary prostate cancer specimens, 3 of 4 distant organ site metastases obtained at autopsy from men died of prostate cancer, and 4 of the 40 matched normal tissues. These results demonstrated that methylation of the 5' CpG island of CD44 gene is closely associated with transcriptional inactivation, resulting in a decreased expression of CD44 in human prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0033562994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033562994&partnerID=8YFLogxK

M3 - Article

C2 - 10344738

AN - SCOPUS:0033562994

VL - 59

SP - 2329

EP - 2331

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 10

ER -